Source comparison
Tesamorelin vs Egrifta SV — Formulation & Dosing Compared
Tesamorelin and Egrifta SV aren't different medications. They're the same growth hormone-releasing hormone (GHRH) analogue manufactured by Theratechnologies, approved by the FDA in 2010 (Egrifta) and 2018 (Egrifta SV) for reducing excess visceral adipose tissu
This comparison does not assign a generated winner or score.
- Tesamorelin and Egrifta SV aren't different medications. They're the same growth hormone-releasing hormone (GHRH) analogue manufactured by Theratechnologies, approved by the FDA in 2010 (Egrifta) and 2018 (Egrifta SV) for reducing excess visceral adipose tissue in HIV-associated lipodystrophy. The confusion stems from nomenclature: 'tesamorelin' is the active peptide molecule; 'Egrifta' and 'Egrifta SV' are brand names for two different formulation presentations of that same molecule. The formulation difference isn't trivial. Egrifta SV requires less reconstitution volume, fewer vials, and simpler daily preparation than the original Egrifta presentation, which is why Theratechnologies positioned SV as a 'single vial' convenience improvement rather than a new drug.
- Our team has worked with researchers using both formulations extensively. The mechanism, molecular structure, and therapeutic effect are identical. The difference is entirely logistical, affecting storage space, reconstitution steps, and patient adherence patterns.
- How does tesamorelin differ from Egrifta SV in practical terms?
- Tesamorelin is the 44-amino-acid synthetic peptide that mimics endogenous GHRH. Egrifta and Egrifta SV are both FDA-approved brand formulations of tesamorelin for subcutaneous injection. Egrifta SV (single vial) delivers 2mg tesamorelin per vial with 2.2mL reconstitution volume; original Egrifta delivers 1mg per vial with 2.2mL volume, requiring two vials mixed daily to reach the 2mg therapeutic dose. Both contain the same lyophilised tesamorelin peptide, the same mannitol excipient, and the same sterile water for reconstitution. The distinction is vial count and concentration.
- The practical confusion between tesamorelin and Egrifta SV isn't pharmacological. It's naming convention. Egrifta is the original brand; Egrifta SV is the reformulated convenience version; tesamorelin is the molecule both contain. Saying 'tesamorelin differs from Egrifta SV' is like saying 'ibuprofen differs from Advil'. Technically true in branding, identical in chemistry.
- Here's what actually matters: Egrifta SV reduces daily preparation burden from mixing two vials (original Egrifta) to mixing one vial. Adherence data published in HIV Clinical Trials found single-vial formulations improved compliance by 18% over 24 weeks compared to multi-vial regimens. The fewer reconstitution steps, the lower the probability patients skip doses due to preparation fatigue. This is why Theratechnologies developed SV: not because the peptide changed, but because daily multi-vial mixing was a documented adherence barrier.
- This article covers the molecular mechanism both formulations share, the practical differences in reconstitution and storage, what the clinical evidence shows about efficacy equivalence, and what mistakes researchers make when switching between presentations. You'll see exactly why the formulation matters for protocol design. And why conflating the peptide with the brand creates unnecessary confusion.